Related Experiment Video

Updated: Jun 23, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

The Dutch Medicines for Children Research Network: a new resource for clinical trials

Elske H Weber1, Ivo T F Timmermans, Martin Offringa

  • 1MCRN - Medicines for Children Research Network, Amsterdam, The Netherlands. e.h.weber@amc.uva.nl

Paediatric Drugs
|May 19, 2009
PubMed

Insights

The Dutch Medicines for Children Research Network (MCRN) was established in 2008 to enhance pediatric clinical drug research. This network aims to improve the speed, quality, and coordination of studies, leading to better healthcare for children.

Area of Science:

  • Pediatric pharmacology
  • Clinical research networks
  • Child health outcomes

Background:

  • European initiatives for pediatric medicine research
  • Need for coordinated clinical trials in children
  • Establishment of national research networks

Purpose of the Study:

  • To improve the speed of clinical drug research in children
  • To enhance the quality of pediatric medicine studies
  • To coordinate clinical drug research efforts for better patient care

Main Methods:

  • Network establishment and launch in September 2008
  • Focus on national coordination of pediatric research
  • Collaboration for clinical drug trials in children

Main Results:

  • The Dutch Medicines for Children Research Network (MCRN) is operational
  • Framework for improved pediatric clinical research established
  • Foundation laid for enhanced drug development for children

Conclusions:

  • The MCRN is poised to advance pediatric medicine research in the Netherlands
  • Improved coordination is key to efficient and high-quality pediatric drug studies
  • The network aims to translate research into improved patient care for children

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...